XOMA (NASDAQ:XOMA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday, March 9th.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
A number of other brokerages also recently issued reports on XOMA. HC Wainwright set a $38.00 price target on XOMA and gave the stock a “buy” rating in a report on Thursday, December 7th. Wedbush reiterated a “buy” rating and set a $33.00 target price on shares of XOMA in a research report on Tuesday, December 19th. TheStreet upgraded XOMA from an “e+” rating to a “c-” rating in a research report on Wednesday, November 29th. Finally, ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $38.33.
NASDAQ:XOMA traded down $0.55 during midday trading on Friday, reaching $19.68. The company had a trading volume of 95,885 shares, compared to its average volume of 188,268. The firm has a market cap of $168.50, a PE ratio of 20.07 and a beta of 3.05. XOMA has a 12-month low of $5.86 and a 12-month high of $37.25. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 2.52.
XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.19. The company had revenue of $5.36 million during the quarter, compared to the consensus estimate of $4.12 million. XOMA had a negative return on equity of 130.44% and a net margin of 27.49%. equities analysts forecast that XOMA will post -1.24 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can acquired a new position in XOMA during the 4th quarter worth approximately $138,000. Acadian Asset Management LLC purchased a new stake in shares of XOMA during the 4th quarter worth approximately $152,000. Gotham Asset Management LLC purchased a new stake in shares of XOMA during the 4th quarter worth approximately $267,000. Wells Fargo & Company MN boosted its stake in shares of XOMA by 4,288.9% during the 4th quarter. Wells Fargo & Company MN now owns 8,295 shares of the biotechnology company’s stock worth $295,000 after acquiring an additional 8,106 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new stake in shares of XOMA during the 4th quarter worth approximately $321,000. Institutional investors own 38.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://theenterpriseleader.com/2018/04/02/xoma-xoma-rating-lowered-to-sell-at-zacks-investment-research.html.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.